<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TOBRAMYCIN SULFATE</span><br/>(toe-bra-mye'sin)<br/><span class="topboxtradename">Tobrex, </span><span class="topboxtradename">TOBI, </span><span class="topboxtradename">Tomycine<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">aminoglycoside antibiotic</span><br/><b>Prototype: </b>Gentamicin sulfate<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL, 40 mg/mL injection; 300 mg/5 mL inhalation solution; 0.3% ophthalmic solution; 3 mg/g ophthalmic ointment</p>
<h1><a name="action">Actions</a></h1>
<p>Broad-spectrum, aminoglycoside antibiotic derived from <i>Streptomyces tenebrarius</i>. Closely related to gentamicin in spectrum of antibacterial activity and pharmacologic properties. Reportedly causes less
         nephrotoxicity than gentamicin, but incidence of ototoxicity is similar. Cross-allergenicity and some cross-resistance among
         aminoglycosides have been demonstrated.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Exhibits greater antibiotic activity against <i>Pseudomonas aeruginosa</i> than other aminoglycosides.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of severe infections caused by susceptible organisms.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to tobramycin and other aminoglycoside antibiotics. Safety during pregnancy (category D) or lactation
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney function; premature and neonatal infants; concurrent use with other neurotoxic or nephrotoxic agents or potent
         diuretics
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 3 mg/kg/d divided q8h up to 5 mg/kg/d infused over 2060 min <span class="rdroute">IM</span> 3 mg/kg/d divided q8h up to 5 mg/kg/d <span class="rdroute">Topical</span> 12 drops in affected eye q14h<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 5 y, 2.5 mg/kg q8h <span class="rdroute">IV</span> <i><img src="../images/special/greaterorequal.gif"/>5 y,</i> 3 mg/kg/d divided q8h up to 5 mg/kg/d infused over 2060 min <span class="rdroute">IM</span> <i><img src="../images/special/greaterorequal.gif"/>5 y,</i> 3 mg/kg/d divided q8h up to 5 mg/kg/d<br/><span class="rdage">Neonate:</span> <span class="rdroute">IM/IV</span> 2.5 mg/kg q1224h<br/><br/><span class="indicationtitle">Cystic Fibrosis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 2.53.5 mg/kg q68h <span class="rdroute">Nebulized</span> 300 mg inhaled b.i.d. times 28 d, may repeat after 28 d drug-free period<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p> 			Note: All doses based on ideal body weight. 		</p><span class="adminroutetype">Instillation</span><br/><ul>
<li>Wash hands before and after instillation of eye medication. Apply gentle finger pressure to lacrimal sac (under inside of
            eyelid) for 1 min after drug has been instilled in eye.
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give deep IM into a large muscle. Rotate injection sites.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 					Note: Verify correct IV concentration and rate of infusion to neonates, infants, or children with physician. 				</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Dilute each dose in 50100 mL or more of D5W, NS or D5/NS. Final concentration should not exceed 1 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Infuse diluted solution over 2060 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Alcohol 5% in dextrose,</b> <span class="classification">cephalosporins</span>, <span class="classification">penicillins</span>, <b>clindamycin,</b> <b>heparin.</b> <span class="incompattype">Y-site:</span> <b>Allopurinol,</b> <b>amphotericin B cholesteryl complex, azithromycin,</b> <span class="classification">cephalosporins</span>, <b>clindamycin,</b> <b>penicillins,</b> <b>heparin hetastarch,</b> <b>indomethacin,</b> <b>propofol,</b> <b>sargramostim.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) prior to reconstitution. After reconstitution, solution may be
            refrigerated and used within 96 h. If kept at room temperature, use within 24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Neurotoxicity (including ototoxicity), <span class="speceff-common">nephrotoxicity,</span> increased AST, ALT, LDH, serum bilirubin; anemia, fever, rash, pruritus, urticaria, nausea, vomiting, headache, lethargy,
      superinfections; hypersensitivity. <span class="typehead">Special Senses:</span> <span class="speceff-common">Burning, stinging of eye after drug instillation;</span> lid itching and edema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">anesthetics</span>, <span class="classification">skeletal muscle relaxants</span> add to neuromuscular blocking effects; <b>acyclovir,</b> <b>amphotericin B,</b> <b>bacitracin,</b> <b>capreomycin,</b> <span class="classification">cephalosporins</span>, <b>colistin,</b> <b>cisplatin,</b> <b>carboplatin,</b> <b>methoxyflurane,</b> <b>polymyxin B,</b> <b>vancomycin,</b> <b>furosemide,</b> <b>ethacrynic acid</b> increased risk of ototoxicity, nephrotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 3090 min IM. <span class="typehead">Duration:</span> Up to 8 h. <span class="typehead">Distribution:</span> Crosses placenta; accumulates in renal cortex. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 23 h in adults. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Weigh patient before treatment for calculation of dosage.</li>
<li>Obtain bacterial C&amp;S tests prior to and during therapy.</li>
<li>Observe patient receiving tobramycin closely because of the high potential for toxicity, even in conventional doses.</li>
<li>Lab tests: Baseline and periodic kidney function; monitor serum drug concentrations to minimize rise of toxicity. Prolonged
            peak serum concentrations &gt;10 mcg/mL or trough concentrations &gt;2 mcg/mL are not recommended.
         </li>
<li>Monitor auditory, and vestibular functions closely, particularly in patients with known or suspected renal impairment and
            patients receiving high doses.
         </li>
<li>Be aware that drug-induced auditory changes are irreversible (partial or total); usually bilateral. In cochlear damage, patient
            may be asymptomatic, and partial or bilateral deafness may continue to develop even after therapy discontinued.
         </li>
<li>Evidence of renal insufficiency, ototoxicity (see Appendix F), or vestibular damage indicates need for dosage adjustment or
            withdrawal of drug.
         </li>
<li>Monitor I&amp;O. Report oliguria, changes in I&amp;O ratio, and cloudy or frothy urine (may indicate proteinuria). Keep patient well
            hydrated to prevent chemical irritation in renal tubules; older adults are especially susceptible to renal toxicity.
         </li>
<li>Monitor patient with neuromuscular disorder (e.g., myasthenia gravis) for muscular weakness. Observe ambulation and assist
            if necessary.
         </li>
<li>Be aware that prolonged use of ophthalmic solution may encourage superinfection with nonsusceptible organisms including fungi.</li>
<li>Report overdose symptoms for eye medication: Increased lacrimation, keratitis, edema and itching of eyelids.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report symptoms of superinfections (see Appendix F) to physician. Prompt treatment with an antibiotic or antifungal medication
            may be necessary.
         </li>
<li>Report S&amp;S of hearing loss, tinnitus, or vertigo to physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>